KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Receivables (2021 - 2025)

Aurinia Pharmaceuticals' Change in Receivables history spans 5 years, with the latest figure at $10.7 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 17483.61% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $4.9 million, down 60.58%, while the annual FY2025 figure was $4.9 million, 60.58% down from the prior year.
  • Change in Receivables reached $10.7 million in Q4 2025 per AUPH's latest filing, up from -$9.4 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $23.6 million in Q3 2022 to a low of -$28.3 million in Q4 2022.
  • Average Change in Receivables over 5 years is $2.1 million, with a median of $3.5 million recorded in 2021.
  • Peak YoY movement for Change in Receivables: plummeted 841.14% in 2024, then skyrocketed 17483.61% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $5.6 million in 2021, then tumbled by 605.05% to -$28.3 million in 2022, then surged by 51.01% to -$13.9 million in 2023, then soared by 100.44% to $61000.0 in 2024, then surged by 17483.61% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Change in Receivables are $10.7 million (Q4 2025), -$9.4 million (Q3 2025), and -$259000.0 (Q2 2025).